GlaxoSmithKline’s (GSK) Neutral Rating Reiterated at JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, Stock Target Advisor reports.

GSK has been the subject of several other reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, August 29th. Cantor Fitzgerald raised GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. New Street Research upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Wednesday. Societe Generale upgraded GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. Finally, ValuEngine lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $41.79.

Shares of NYSE GSK opened at $42.53 on Thursday. The stock has a market capitalization of $105.43 billion, a PE ratio of 13.46, a P/E/G ratio of 2.02 and a beta of 0.68. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48. The business has a fifty day moving average price of $41.82 and a two-hundred day moving average price of $40.79. GlaxoSmithKline has a fifty-two week low of $36.41 and a fifty-two week high of $43.22.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. On average, equities analysts expect that GlaxoSmithKline will post 2.97 EPS for the current year.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 177,777 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were bought at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in GlaxoSmithKline by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock worth $610,776,000 after acquiring an additional 989,181 shares during the last quarter. Morgan Stanley grew its position in GlaxoSmithKline by 5.8% during the 2nd quarter. Morgan Stanley now owns 3,845,882 shares of the pharmaceutical company’s stock worth $153,912,000 after acquiring an additional 212,166 shares during the last quarter. Eaton Vance Management grew its position in GlaxoSmithKline by 6.8% during the 2nd quarter. Eaton Vance Management now owns 2,229,470 shares of the pharmaceutical company’s stock worth $89,034,000 after acquiring an additional 141,256 shares during the last quarter. Jane Street Group LLC grew its position in GlaxoSmithKline by 7,574.0% during the 2nd quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock worth $72,693,000 after acquiring an additional 1,792,754 shares during the last quarter. Finally, Kahn Brothers Group Inc. DE grew its position in GlaxoSmithKline by 25.7% during the 2nd quarter. Kahn Brothers Group Inc. DE now owns 1,605,014 shares of the pharmaceutical company’s stock worth $64,233,000 after acquiring an additional 328,464 shares during the last quarter. Institutional investors own 11.13% of the company’s stock.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: How the Consumer Price Index (CPI) is calculated?

Stock Target Advisor

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.